Table 1.

Number of serious and minor adverse events in children aged 12–24 months participating in an anthelminthic trial in Peru (2011–2013), by intervention group

	MEB/PBO*	PBO/MEB†	MEB/MEB‡	PBO/PBO§
Serious adverse events	7	1	5	5
Death	5	1	3	2
Hospitalization	2	0	2	3
Minor adverse events	5	9	9	8
Total adverse events	12	10	14	13

^*Group 1 (MEB/PBO): mebendazole at the 12-month visit and placebo at the 18-month visit.

^†Group 2 (PBO/MEB): placebo at the 12-month visit and mebendazole at the 18-month visit.

^‡Group 3 (MEB/MEB): mebendazole at the 12- and 18-month visits.

^§Group 4 (PBO/PBO): placebo at the 12- and 18-month visits.